Potential Cardiovascular Benefits of Vasopressin Receptor Antagonism, Sodium-Glucose Cotransporter Inhibitors, and Mineralocorticoid Receptor Antagonists in ADPKD. This evidence concerns the gene NR3C2 and autosomal dominant polycystic kidney disease.